GoodRx Holdings, Inc. GDRX
At closeNov 3, 2026, 4:39 PM EST
After hours · Nov 3, 4:39 PM ET
- YTD
- +28.78%
- 1 year
- +5.44%
- Market cap
- 1.19B
- Revenue (ttm)
- 785.23M
- Profit margin
- 2.07%
- EPS (ttm)
- 0.05
- Shares out
- 107.18M
- P/E ratio
- 69.80
- Forward P/E
- 9.91
- YTD return
- +28.78%
- 1-year return
- +5.44%
- Volume
- 1.03M
- Avg volume
- 1.30M
- Open
- 3.53
- Previous close
- 3.55
- Day's range
- 3.45 – 3.59
- 52-week range
- 1.77 – 3.89
- Beta
- 1.66
- Analysts
- Hold
- Price target
- 3.95 (+13.2%)
- Earnings date
- Nov 3, 2026
6M +1.01 (+40.40%)
Key statistics
- Enterprise value
- 1.45B
- PEG ratio
- 0.00
- Price / sales
- 1.52
- Price / book
- 1.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.30%
- Free cash flow
- 112.50M
- Total cash
- 296.11M
- Total debt
- 538.95M
- Return on equity
- 2.52%
- Short % of float
- 3.83%
- 50-day average
- 3.43
- 200-day average
- 2.82
Analyst view
Consensus: hold
- Target (low)
- 2.65
- Target (mean)
- 3.95
- Target (high)
- 5.00
- Strong buy1
- Buy3
- Hold8
- Sell0
- Strong sell2
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.07787.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.07787 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.07968 | 0.08 | 0.00 | +0.40% |
| May 6, 2026 | Mar 31, 2026 | 0.07 | 0.07 | 0.00 | 0.00% |
| Feb 25, 2026 | Dec 31, 2025 | 0.09 | 0.09 | 0.00 | 0.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.09 | 0.08 | -0.01 | -11.11% |
| Aug 6, 2025 | Jun 30, 2025 | 0.10 | 0.09 | -0.01 | -10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 2026 | Barclays | main | Underweight | Underweight |
| Aug 13, 2026 | UBS | main | Neutral | Neutral |
| Aug 11, 2026 | Citigroup | main | Buy | Buy |
| Aug 11, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | Wells Fargo | main | Overweight | Overweight |
| May 14, 2026 | Citigroup | main | Buy | Buy |
About GoodRx Holdings, Inc.
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- goodrx.com
News
GoodRx Holdings Is Going Through A Painful Transition That Will Pay Off 
GoodRx Rolls Out Its Employer Direct Weight Loss Offering For GLP-1 Medications 
GoodRx Launches Employer Direct Weight Loss Offering 
Full Transcript: GoodRx Holdings Q2 2026 Earnings Call 
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips 
GoodRx Covers Whole Households and Pets in New Prescription Plan 
GoodRx offers health subscription for families, to launch as employee benefit in 2027 
From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household 
Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4 
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75
Your note
Sign in to keep a note on GDRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNES WENDY LYNN | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 14, 2026 | 741,657 |
| BEZDEK TREVOR | Director | Stock Award(Grant) | Jun 15, 2026 | 5,609,250 |
| BRUEHLMAN RONALD E | Director | Stock Award(Grant) | Jun 15, 2026 | 207,352 |
| HIRSCH DOUGLAS JOSEPH | Director | Conversion of Exercise of derivative security | Oct 25, 2026 | 5,606,900 |
| KENNEDY KELLY J | Director | Stock Award(Grant) | Jun 15, 2026 | 207,645 |
| MCGINNIS CHRISTOPHER ALAN | Chief Financial Officer | Conversion of Exercise of derivative security | Jul 14, 2026 | 198,310 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Francisco Partners Management, LP | 57.38% | 60,078,184 | 209.67M | Jun 29, 2026 |
| LSV Asset Management | 4.92% | 5,156,711 | 18.00M | Jun 29, 2026 |
| Ameriprise Financial, Inc. | 4.53% | 4,746,330 | 16.56M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.90% | 4,086,521 | 14.26M | Jun 29, 2026 |
| Silver Lake Group, LLC | 3.37% | 3,532,276 | 12.33M | Jun 29, 2026 |
| Renaissance Technologies, LLC | 3.10% | 3,245,738 | 11.33M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80% | 2,928,540 | 10.22M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1.21% | 1,264,093 | 4.41M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.01% | 1,060,122 | 3.70M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.97% | 1,019,780 | 3.56M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 0.62% | 646,856 | 2.26M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 0.53% | 559,164 | 1.95M | Jul 30, 2026 |